Shares of Echo IQ surged 10.2% to A$0.48 on Monday after the Australian medical-AI company released its September-quarter update, reporting a sharp jump in the number of heart scans processed by its flagship software and flagging deeper inroads into the U.S. hospital market. The question now: whether volume growth translates into durable income before the cash pile shrinks. Echo IQ's Heart-Scan Volumes Nearly Triple, but Can This Cash-Burning AI Startup Convert Hospital Buzz Into Real Revenue?
Shares of Echo IQ jumped 10.2% to A$0.48 after the Australian AI-cardiology company released its September-quarter update, reporting a near-tripling in heart scans processed by its software and a freshly fortified balance sheet. For a company still essentially pre-revenue, the question is whether soaring usage numbers can close the gap between hospital interest and paying contracts.
• Scan Volumes Are Surging, but the Revenue Line Remains Barely Visible. The company reported 9,697 completed assessments during the quarter — software-generated reports that flag dangerous heart-valve narrowing called aortic stenosis — up roughly 193% year on year. The prior quarter had already shown over 10,200 scans processed, up more than 400% year on year. Yet EIQ remains pre-revenue, with FY25 revenue of just A$91,000 and a net loss of A$13.3 million. High assessment counts prove hospitals are trialling the tool, not that they are paying for it at scale.
• A$107.8 Million in Cash Buys Time — but the Burn Clock Is Ticking. Echo IQ raised A$110 million through an institutional placement in July 2026 to fund U.S. expansion, leaving it with roughly A$107.8 million at quarter-end. Net cash used in operating activities was about A$2.7 million per quarter last fiscal year, with only an estimated 3.2 quarters of funding at that earlier burn rate. The fresh capital dramatically extends the runway, but investors should watch whether spending accelerates alongside the U.S. push.
• The FDA Setback on Heart Failure Adds Strategic Uncertainty. The FDA issued a "Not Substantially Equivalent" determination for Echo IQ's next-generation heart-failure screening product in September 2026.
The company believes clearance "could potentially be achieved over the coming quarters," but a delay narrows the product pipeline to a single approved tool and raises the stakes on near-term commercialisation of the existing product.
• U.S. Hospital Pipeline Looks Promising but Unproven. Echo IQ has expanded its pipeline to over 70 U.S. hospitals, including three enterprise proposals covering more than 300 hospitals.
A binding agreement with Pro Medicus — a major medical-imaging platform — adds up to A$20 million in investment and a commercial partnership. Converting trials into subscription contracts will be the definitive test of whether this stock deserves its +127% year-to-date gain — or whether the market has priced in a future that hasn't arrived.